Krystal Biotech, Inc. — Earnings Quality Grade B
KRYS · Healthcare
Generally healthy
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 120 days, change -12 days YoY
AR growth 21.7% vs revenue growth 33.9%
Revenue 33.9%, CFFO 62.7%. Cash follows revenue
Expense Quality
Inventory growth 52.7% exceeds COGS 14.9%
CapEx growth 182.0% is >2x revenue growth 33.9%
SG&A/Gross Profit = 40.1%. Normal
Gross margin 94.1%, change +1.0pp. Stable
Cash Flow Quality
CFFO/NI = 0.98. Profits backed by cash
FCF $0.2B, FCF/NI = 0.92
Accruals ratio = 0.3%. Low accruals
Cash $0.8B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 0.1x. Healthy
Other assets 24.2% vs revenue 33.9%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
No goodwill
Manipulation Score
M-Score = -2.27 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25